ciprofol

Ciprofol (Chinese name: 环泊酚) is a novel, short-acting intravenous anesthetic and sedative developed in China. It is a small molecule drug and an (R)-isomeric compound structurally related to propofol but with a cyclopropyl group that enhances its pharmacological properties[1][9]. Ciprofol acts as an agonist at the gamma-aminobutyric acid type A receptor (GABAA receptor), increasing chloride ion conductance through the channel, leading to neuronal hyperpolarization and central nervous system depression. This results in anesthesia and sedation effects[1][6]. Compared to propofol, ciprofol has similar or superior efficacy for induction and maintenance of general anesthesia as well as procedural sedation (e.g., gastrointestinal endoscopy), with advantages including faster onset/recovery, lower incidence of injection pain, less circulatory depression, reduced respiratory adverse events, and improved patient comfort[2][4][10]. It has been approved for use in China for induction and maintenance of general anesthesia as well as sedation during gastrointestinal endoscopy; other indications such as ICU sedation are under regulatory review or clinical development[6][8].

Brand names

思舒宁

Other names

环泊酚ciprofol injectionHSK3486HSK-3486HSK 3486